Remote Biotech Jobs (Hiring Now, Jan 2025): Find the best work from home or hybrid full & part-time jobs. Discover a better job search with FlexJobs!
Companies should prioritize leveraging the TGA’s efficiency to expedite timelines while using Australian trial results to support global regulatory submissions, including subsequent filings with the US Food and Drug Administration. Leverage Tax Incentives The R&D Tax Incentive can be a game-changer for ...
Jan. 30 - Quince Therapeutics:The biotech, formerly known as Cortexyme, is laying off 47% of its staff as part of a cost reduction plan. The layoffs will start in February and be completed by April.Story Jan. 30 - Amgen:The threat of layoffs continues to loom for companies large and...
mid, small cap companies, when I think about biotech, it is more about development stages, so to me, there are maybe five, distinct development stages, which is reflected by their valuation (broad strokes; there are always exceptions): ...
for me in what they like today, except on the investments that I made five years ago. I used to come to this conference and spend lots of time with those folks and I do not do that anymore. It’s the portfolio companies that have to spend time with those folks, not me. Because in...
The startup has 18 full-time staffers and plans to “continue to grow steadily,” aiming to hit about 25 people by the end of the year. The hiring spree will hopefully include bringing on a full-time CEO in the near future, Kotz said. Jnana is currently helmed by Amir Nashat, a par...
Hiring. This would seem to be a big one, especially in hotly competitive geographies such as Cambridge or the Bay Area. But now that more and more “virtual drug development” companies are filing for IPO in Phase 2 with staffs of fewer than fifteen people – two of these have beenCBT ...
businesses have been forced to re-think many longstanding systems that serve to perpetuate inequality in so many ways, which usually aren’t caught on cell phone video. Hiring, retention, and promotion are obvious places where companies have control, and a chance to make good on many stated ...
In the near term, the biotech has built out its scientific advisory board, moved into a new space and is hiring aggressively to fulfill the obligations of the strategic partnership. Investors:Arch Venture Partners, Cardinal Partners, Versant Ventures ...
What makes them different from other companies working in this area? “We’re going after personalized approaches both on the vaccine side as well as on the T-cell therapy side, and we are really becoming leaders I think in the space of some of the key components that you need to make ...